PARIS (Agefi-Dow Jones)–Valneva announced on Wednesday that the European Commission has ordered 1.25 million doses of its Covid-19 vaccine for 2022, following negotiations after the Brussels decision. to terminate its original purchase agreement with the pharmaceutical company.
Valneva had entered into an advance purchase agreement with the European Commission in November 2021 for the supply of up to 60 million doses of its inactivated whole-virus vaccine, VLA2001, against Covid-19. But the European Commission announced in May its intention to terminate the agreement.
After discussions and as part of an addendum to the agreement, Valneva said on Wednesday that participating member states would eventually order “1.25 million doses of VLA2001 in 2022 and[aient] the possibility of ordering and having an identical quantity delivered later this year”.
“Valneva will maintain stocks for possible additional supply from Member States if demand increases, and will at the same time endeavor to sell approximately eight to ten million doses on international markets,” added the group.
In June, the European Commission authorized the marketing of Valneva’s Covid-19 vaccine as a primary series for adults aged 18 to 50.
-Jerome Batteau, Agefi-Dow Jones; 01 41 27 47 92; [email protected] ed: LBO
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
July 20, 2022 12:50 ET (16:50 GMT)